Bayer Healthcare LLC v. Baxalta Inc.
989 F.3d 964
Fed. Cir.2021Background
- Patent No. 9,364,520 claims recombinant human factor VIII (FVIII) conjugated to a polyalkylene oxide (PEG) covalently attached "at the B-domain," asserting site-directed (non-random) PEGylation that retains FVIII activity and improves half-life.
- Claim 1 recites an "isolated polypeptide conjugate" comprising SEQ ID NO:4 (or allelic variant) with PEG attached at the B-domain; the specification criticizes "random" PEGylation (e.g., targeting lysines) for producing heterogeneous, lower-activity products and discloses cysteine-based site-directed PEGylation examples.
- Baxalta’s product Adynovate® is a PEGylated rFVIII made by PEGylating amine groups (including lysines); Bayer sued for infringement. District court construed "isolated polypeptide conjugate" to mean non-random conjugation and "at the B-domain" to require retention of FVIII activity.
- At trial the jury found infringement and that the asserted claims were enabled, awarding $155,190,264 (June 14, 2016–Nov. 30, 2018) based on a 17.78% royalty; district court granted JMOL of no willfulness and later awarded $18,324,562 supplemental (pre-judgment) damages for Dec.1, 2018–Feb.8, 2019.
- Both parties appealed (Baxalta challenging claim construction, infringement, enablement, damages and supplemental damages; Bayer cross-appealed the JMOL of no willfulness). The Federal Circuit affirmed.
Issues
| Issue | Bayer's Argument | Baxalta's Argument | Held |
|---|---|---|---|
| Construction of "at the B-domain" | Term covers PEG attached to the B-domain as a region; not limited to specific amino acids | Term should exclude amine/lysine PEGylation (i.e., exclude conjugation at amines/carboxys) | Affirmed: claim language, spec, prosecution history do not exclude non-random amine/lysine PEGylation; construction stands |
| Meaning of "random" in "isolated polypeptide conjugate" | Court’s construction (non-random) is sufficient; jury may decide factual application | Court should define "random" more narrowly (e.g., any conjugation at amines/carboxys) | Affirmed: court properly declined further definition after resolving key disputes (non-random does not require total homogeneity) |
| Infringement (JMOL) | Adynovate is made by non-random, B-domain–predominant PEGylation; FDA submissions and analytical data support region-specific, controlled process | Adynovate results from random amine/lysine PEGylation and thus falls outside claim scope | Affirmed: substantial evidence supports jury verdict of infringement (company admissions, FDA filings, expert testimony) |
| Enablement (JMOL) | Specification plus skilled-artisan knowledge enable full claim scope (including non-random lysine PEGylation); working cysteine examples bridge to lysine | Spec lacks working examples for lysine PEGylation; would require undue experimentation | Affirmed: substantial evidence supports jury finding of enablement (spec examples, prior art, expert testimony on predictability and routine experimentation) |
| Damages methodology (expert range) | Expert provided a defensible bargaining range; jury may pick within range | Expert’s 50/50 midpoint excluded; allowing jury to choose within range was improper or speculative | Affirmed: district court did not abuse discretion admitting range testimony; jury award within expert’s range supported by evidence |
| Pre-verdict supplemental damages (Seventh Amendment/additur) | Award based on actual post-verdict sales × jury’s rate is proper; court may compute damages not determined by jury | Award is an impermissible additur that invades right to jury trial | Affirmed: no Seventh Amendment violation—court lawfully applied jury’s royalty rate to undisputed post-verdict sales and acted within discretion |
| Willfulness (JMOL) | Evidence of knowledge of patent and targeted shift to B-domain supports willfulness | Knowledge and infringement alone insufficient to show deliberate, wanton intent to infringe | Affirmed: record insufficient to permit jury to find willfulness; JMOL for no willfulness proper |
Key Cases Cited
- Hologic, Inc. v. Minerva Surgical, Inc., 957 F.3d 1256 (Fed. Cir. 2020) (claim construction based on intrinsic evidence reviewed de novo)
- O2 Micro Int’l Ltd. v. Beyond Innovation Tech. Co., 521 F.3d 1351 (Fed. Cir. 2008) (court must resolve fundamental claim-scope disputes)
- Eon Corp. IP Holdings v. Silver Spring Networks, Inc., 815 F.3d 1314 (Fed. Cir. 2016) (ultimate question of claim construction is legal)
- Indivior Inc. v. Dr. Reddy’s Laboratories, S.A., 930 F.3d 1325 (Fed. Cir. 2019) (specification disparagement can produce clear disclaimer limiting claims)
- SciMed Life Systems, Inc. v. Advanced Cardiovascular Systems, Inc., 242 F.3d 1337 (Fed. Cir. 2001) (specification can unequivocally disclaim embodiments)
- Gaus v. Conair Corp., 363 F.3d 1284 (Fed. Cir. 2004) (disclaimer precludes reliance on equivalents for disclaimed embodiments)
- Halo Elecs., Inc. v. Pulse Elecs., Inc., 136 S. Ct. 1923 (2016) (willfulness requires specific intent; standard for enhanced damages)
- Idenix Pharms. LLC v. Gilead Scis. Inc., 941 F.3d 1149 (Fed. Cir. 2019) (standards for JMOL review and enablement factual inquiries)
- Powell v. Home Depot U.S.A., Inc., 663 F.3d 1221 (Fed. Cir. 2011) (jury may choose damages within parties’ advocated ranges)
- Rembrandt Wireless Techs., LP v. Samsung Elecs. Co., 853 F.3d 1370 (Fed. Cir. 2017) (jury award within expert’s suggested range can be supported by substantial evidence)